Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 109,755 shares […]